Glyburide Compared to Insulin for the Treatment of Gestational Diabetes Mellitus: A Cost Analysis
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objective To compare the costs associated with glyburide compared to insulin for the treatment of gestational diabetes unresponsive to dietary therapy. Study design A cost model was designed. The model excluded costs that were identical for both treatment arms, such as the cost of monitoring glucose control. Insulin treatment costs included average wholesale drug costs, wholesale delivery costs (syringes, alcohol pads), and costs of office staff educating patients. Glyburide costs were based on average wholesale drug costs. Downstream costs of potential inpatient evaluation for hypoglycemia were included in the model. Results In our baseline model, glyburide was significantly less costly than insulin for the treatment of gestational diabetes. The average cost saving per patient based on wholesale drug costs and hospital costs was US$165.84. Actual retail drug savings and hospital charge savings are potentially considerably greater. The strongest determinant of cost savings was medication cost. The model was less sensitive to the one-time costs of inpatient treatment and patient education. Conclusion Glyburide is less costly than insulin for the treatment of gestational diabetes. Cost models can be useful to physicians deciding between two equally efficacious medications, allowing them to incorporate information about their individual practice styles with a complex balance of cost implications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compared with insulin, glyburide may be more convenient, is less expensive (184)”
From Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline (2013) · cites this paper as [184]
Citations
Cites
1 retracted
ACOG Practice Bulletin No. 30: Gestational Diabetes
(2001) · Obstetrics & Gynecology · doi:10.1097/00006250-200109000-00037 · Cited by 301
RetractedA comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924 · cited 8×
“The cost of glyburide failure necessitating subsequent insulin treatment was modeled based on a 5-week trial of glyburide as described in Langer et al. Patients switching to insulin incurred the educational costs of an insulin new start.”
BackgroundMethodInfluentialSchaefer-Graf, U. M., Buchanan, T. A., Xiang, A., Songster, G., Montoro, M., & Kjos, S. L. (2000) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(00)70217-1 · Cited by 270
Effects of in-utero exposure to oral hypoglycaemic drugs
Piacquadio, K. M., Hollingsworth, D. R., & Murphy, H. (1991) · The Lancet · doi:10.1016/0140-6736(91)91512-s · Cited by 139
American Diabetes Association (1998) · Diabetes Care · doi:10.2337/diacare.21.1.s60 · Cited by 114
Prolonged Symptomatic Neonatal Hypoglycemia Associated with Maternal Chlorpropamide Therapy
Zucker, P., & Simon, G. (1968) · Pediatrics · doi:10.1542/peds.42.5.824 · Cited by 80 · cited 1×
“Until recently, oral therapy with sulfonylurea drugs had been contraindicated due to concerns regarding teratogenicity(3,4) and the possibility of neonatal hypoglycemia.(5) However, a recent report by Langer et al.”
Background
Cited by
Hod, M., Kapur, A., Sacks, D. A., Hadar, E., Agarwal, M., Di Renzo, G. C., Roura, L. C., McIntyre, H. D., Morris, J. L., & Divakar, H. (2015) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(15)30033-3 · Cited by 767
Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline
Blumer, I., Hadar, E., Hadden, D. R., Jovanovič, L., Mestman, J. H., Murad, M. H., & Yogev, Y. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2465 · Cited by 561
“Compared with insulin, glyburide may be more convenient, is less expensive (184), does not require intensive educational instruction at initiation of therapy, and is preferred by most patients (179, 183).”
The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus
Rendell, M. (2004) · Drugs · doi:10.2165/00003495-200464120-00006 · Cited by 308
Tarry-Adkins, J. L., Aiken, C. E., & Ozanne, S. E. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002848 · Cited by 251
Insulin and glyburide therapy: Dosage, severity level of gestational diabetes, and pregnancy outcome
Langer, O., Yogev, Y., Xenakis, E. M.-J., & Rosenn, B. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.07.011 · Cited by 140
Camelo Castillo, W., Boggess, K., Stürmer, T., Brookhart, M. A., Benjamin, D. K., & Jonsson Funk, M. (2014) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000000285 · Cited by 118
“Its ease of use and low cost are advantages compared with insulin, which is administered by injection and entails higher costs.(8) In 2000, Langer et al(9) conducted the first randomized controlled trial comparing glyburide with insulin in 404 women with GDM.”
Sénat, M.-V., Affres, H., Letourneau, A., Coustols-Valat, M., Cazaubiel, M., Legardeur, H., Jacquier, J. F., Bourcigaux, N., Simon, E., Rod, A., et al. (2018) · JAMA · doi:10.1001/jama.2018.4072 · Cited by 114
Management of Gestational Diabetes: Pharmacologic Treatment Options and Glycemic Control
Langer, O. (2006) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.09.007 · Cited by 96
“Goetzel and Wilkins [114] compared the costs of insulin and glyburide and observed that glyburide is considerably less costly (average savings per patient of $166–$200 based on rates in 2000).”
BackgroundRochon, M., Rand, L., Roth, L., & Gaddipati, S. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.07.029 · Cited by 82
The use of glyburide in the management of gestational diabetes mellitus: A meta-analysis
Zeng, Y.-C., Li, M.-J., Chen, Y., Jiang, L., Wang, S.-M., Mo, X.-L., & Li, B.-Y. (2014) · Advances in Medical Sciences · doi:10.1016/j.advms.2014.03.001 · Cited by 76
Glyburide as treatment option for gestational diabetes mellitus
Tempe, A., & Mayanglambam, R. D. (2013) · Journal of Obstetrics and Gynaecology Research · doi:10.1111/jog.12042 · Cited by 71
“It constitutes a high-risk group affecting 3–5% of pregnant women.(1,2) Approximately 0.”
BackgroundScreening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
Waugh, N., Royle, P., Clar, C., Henderson, R., Cummins, E., Hadden, D., Lindsay, R., & Pearson, D. (2010) · Health Technology Assessment · doi:10.3310/hta14450 · Cited by 60
“Goetzl and Wilkins (2002)117 undertook a decision tree analysis of the costs of glyburide therapy compared with insulin therapy for patients with gestational diabetes.”
Gestational diabetes mellitus: Non-insulin management
Magon, N., & Seshiah, V (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.85580 · Cited by 58
“A cost analysis was then performed by Goetzl to compare the costs associated with glyburide versus insulin therapy.[55] Glyburide was found to be significantly less costly than insulin, with an average cost savings per patient of $165.”
MethodMukhopadhyay, P., Bag, T. S., Kyal, A., Saha, D. P., & Khalid, N. (2012) · Journal of South Asian Federation of Obstetrics and Gynaecology · doi:10.5005/jp-journals-10006-1167 · Cited by 56
Liao, L. D., Ferrara, A. M., Greenberg, M., Ngo, A. L., Feng, J., Zhang, Z., Bradshaw, P. T., Hubbard, A., & Zhu, Y. (2022) · BMC Medicine · doi:10.1186/s12916-022-02499-7 · Cited by 51
“Given notable advantages of the ease of use, lower cost, and acceptance among patients [9, 10], the prevalence of glyburide use for GDM treatment increased from 7.”
BackgroundTratamento do diabetes melito gestacional
Maganha, C. A., Vanni, D. G. B. S., Bernardini, M. A., & Zugaib, M. (2003) · Revista da Associação Médica Brasileira · doi:10.1590/s0104-42302003000300040 · Cited by 59
Oral Hypoglycemic Agents in Pregnancy
Refuerzo, J. (2011) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2011.02.013 · Cited by 33
“A cost analysis was then performed by Goetzl to compare the costs associated with glyburide versus insulin for the treatment of gestational diabetes.(20) They found that glyburide was significantly less costly than insulin.”
MethodOral Agents for the Treatment of Gestational Diabetes
Finneran, M. M., & Landon, M. B. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1093-2 · Cited by 36
Pharmacological Management of Gestational Diabetes Mellitus
Mukerji, G., & Feig, D. S. (2017) · Drugs · doi:10.1007/s40265-017-0807-0 · Cited by 41
“OADS are increasingly being used as first-line therapy for GDM as they are more convenient, less expensive, and can be more acceptable to use in terms of administration and storage compared to insulin injection therapy [45, 46].”
MethodGlyburide in gestational diabetes—prediction of treatment failure
Yogev, Y., Melamed, N., Chen, R., Nassie, D., Pardo, J., & Hod, M. (2011) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2010.531323 · Cited by 25
“In addition, glyburide is associated with lower cost [2], decreased risk of hypoglycemia [1,3], and ease of administration compared with insulin.”
BackgroundCurrent management of gestational diabetes mellitus
Menato, G., Bo, S., Signorile, A., Gallo, M., Cotrino, I., Poala, C. B., & Massobrio, M. (2008) · Expert Review of Obstetrics & Gynecology · doi:10.1586/17474108.3.1.73 · Cited by 24
Helal, K. F., Badr, M. S., Rafeek, M. E.-S., Elnagar, W. M., & Lashin, M. E.-B. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-019-05430-3 · Cited by 17
Pharmacological Management of Gestational Diabetes Mellitus
Bergel, R., Hadar, E., Toledano, Y., & Hod, M. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0802-y · Cited by 19
Gestational Diabetes Management: Guidelines to a Healthy Pregnancy
Scollan‐Koliopoulos, M., Guadagno, S., & Walker, E. A. (2006) · The Nurse Practitioner · doi:10.1097/00006205-200606000-00004 · Cited by 20
“Glyburide was significantly less costly than insulin for treating gestational diabetes.(36,41) Glyburide is contraindicated in patients reporting an allergy to sulfa.”
BackgroundOral Antidiabetic Drugs in Pregnancy: The Other Alternative
Langer, O. (2007) · Diabetes Spectrum · doi:10.2337/diaspect.20.2.101 · Cited by 12
Using Oral Agents to Manage Gestational Diabetes: What Have We Learned?
Buschur, E., Brown, F. M., & Wyckoff, J. (2015) · Current Diabetes Reports · doi:10.1007/s11892-014-0570-5 · Cited by 10
Can Pregnant Diabetics be Treated with Glyburide?
Melamed, N., & Yogev, Y. (2009) · Women s Health · doi:10.2217/whe.09.55 · Cited by 9
“Since glyburide is considerably more convenient and less expensive than insulin [51], it is clearly preferred by most patients [47,49], and can thus lead to increased patient compliance.”
BackgroundLin, B., & Zhang, X. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s397255 · Cited by 7
Wu, R., & Li, Z. (2024) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-024-07483-5 · Cited by 8
“The hospitalization and treatment duration costs were retrieved from a cost analysis by Goetzl et al. [26].”
Faraji, A., Tahamtani, L., Maharlouei, N., & Asadi, N. (2022) · Obstetric Medicine · doi:10.1177/1753495x221100167 · Cited by 7
“The first-line treatment of GDM remains controversial, although commonly subcutaneous insulin, this is expensive and multiple injections are not easy or comfortable.(10) Oral hypoglycemic agents such as glibenclamide have been tested extensively but their results remain inconclusive.”
BackgroundEnrique Valdés, R., Soto-Chacón, E., Lahsen, R., Carlos Barrera, H., & Paula Candia, P. (2008) · Revista médica de Chile · doi:10.4067/s0034-98872008000700015 · Cited by 9
Thomas, A. M. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-112-3_10 · Cited by 6
Pharmacological therapy in gestational diabetes – a comparison between insulin and oral therapy
Shmuel, E., Krispin, E., Toledano, Y., Chen, R., Wiznitzer, A., & Hadar, E. (2021) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2021.1875208 · Cited by 7
“The reasons for this are: ease of use and storage, increased patient responsiveness, and lower cost [10,24,25].”
BackgroundPregnancy complicated by diabetes mellitus
Langer, O. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06545-0.00025-x · Cited by 5
Odiba, J. O., & Mabhala, M. A. (2015) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2015.52007 · Cited by 3
Gao, Y., Wang, K., Chen, Y., Shen, L., Hou, J., Xuan, J., & Liu, B. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0382-8 · Cited by 3
Rao, P. S., Datta, S., & Prajwal, S. (2017) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20171420 · Cited by 2
7. Management of hyperglycemia during pregnancy
(2015) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(15)30015-1 · Cited by 3
Buitrago-Leal, M., & Giraldo, S. M. (2014) · Repositorio Digital de la Fundación Universitaria de Ciencias de la Salud (FUCSALUD) · Cited by 5
Oral anti-diabetic agents in pregnancy: Their time has come
Langer, O. (2008) · Series in maternal-fetal medicine · doi:10.3109/9781439802007.028 · Cited by 2
(2008) · Elsevier eBooks · doi:10.1016/b978-032304306-9.50012-4 · Cited by 2
Glyburide Is a Safe and Effective Treatment for Gestational Diabetes
Kelly, L. (2008) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)32733-5 · Cited by 2
Pharmacological Treatment Options for Gestational Diabetes
Langer, O. (2010) · Springer eBooks · doi:10.1007/978-1-84882-120-0_19
Comparison of insulin and glibenclamide in gestational diabetes mellitus
Alauddin, N. (2021) · International Journal of Clinical Obstetrics and Gynaecology · doi:10.33545/gynae.2021.v5.i1a.787
“[1] Pregnancy causes incremental improvements to the metabolism of the maternal carbohydrate to satisfy the increasing demands of the foetus and her mother.”
BackgroundLiao, L. D., Ferrara, A., Greenberg, M., Ngo, A. L., Feng, J., Zhang, Z., Bradshaw, P. T., Hubbard, A. E., & Zhu, Y. (2022) · Figshare · doi:10.6084/m9.figshare.21117779
Liao, L. D., Ferrara, A., Greenberg, M., Ngo, A. L., Feng, J., Zhang, Z., Bradshaw, P. T., Hubbard, A. E., & Zhu, Y. (2022) · Figshare · doi:10.6084/m9.figshare.21117806
Liao, L. D., Ferrara, A., Greenberg, M., Ngo, A. L., Feng, J., Zhang, Z., Bradshaw, P. T., Hubbard, A. E., & Zhu, Y. (2022) · Figshare · doi:10.6084/m9.figshare.21117812
Liao, L. D., Ferrara, A., Greenberg, M., Ngo, A. L., Feng, J., Zhang, Z., Bradshaw, P. T., Hubbard, A. E., & Zhu, Y. (2022) · Figshare · doi:10.6084/m9.figshare.21117809
Liao, L. D., Ferrara, A., Greenberg, M., Ngo, A. L., Feng, J., Zhang, Z., Bradshaw, P. T., Hubbard, A. E., & Zhu, Y. (2022) · Figshare · doi:10.6084/m9.figshare.21117794
Liao, L. D., Ferrara, A., Greenberg, M., Ngo, A. L., Feng, J., Zhang, Z., Bradshaw, P. T., Hubbard, A. E., & Zhu, Y. (2022) · Figshare · doi:10.6084/m9.figshare.21117791
Liao, L. D., Ferrara, A., Greenberg, M., Ngo, A. L., Feng, J., Zhang, Z., Bradshaw, P. T., Hubbard, A. E., & Zhu, Y. (2022) · Figshare · doi:10.6084/m9.figshare.21117785
Liao, L. D., Ferrara, A., Greenberg, M., Ngo, A. L., Feng, J., Zhang, Z., Bradshaw, P. T., Hubbard, A. E., & Zhu, Y. (2022) · Figshare · doi:10.6084/m9.figshare.21117797
Liao, L. D., Ferrara, A., Greenberg, M., Ngo, A. L., Feng, J., Zhang, Z., Bradshaw, P. T., Hubbard, A. E., & Zhu, Y. (2022) · Figshare · doi:10.6084/m9.figshare.21117803
Metadata
- Authors
- Goetzl, L., & Wilkins, I.
- Affiliations
- Baylor College of Medicine (US)
- ORCID
- Goetzl, Laura
- Venue
- Journal of Perinatology
- Published
- 2002-06-27
- Volume
- 22
- Issue
- 5
- Pages
- 403-406
- ISSN
- 0743-8346 (ISSN-L)
- 1476-5543
- OpenAlex
- W2061072286
- Cited by
- 54
- References
- 6
- Citations by year
- 2024: 1 · 2023: 1 · 2022: 11 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 2 · 2016: 1 · 2015: 4 · 2014: 3 · 2013: 3 · 2012: 1
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Journal of Perinatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Keywords
- gestational diabetes mellitus, glibenclamide, insulin, cost comparison, cost model, hypoglycemia, drug costs, patient education, hospital costs
- MeSH terms
- Costs and Cost Analysis, Female, Glyburide, Hospitalization, Humans, Hypoglycemic Agents, Insulin, Pregnancy, Texas, Diabetes, Gestational, Hospital Charges, Models, Economic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.